Bleeding owing to portal hypertensive colopathy, a form of large bowel angiodysplasia, as a cause of increased blood transfusion requirement is described in a 74 year old man with idiopathic myelofibrosis. The proposed mechanism and the potential therapeutic options for this rare complication of myelofibrosis are discussed.

Angiodysplasia

Myeloproliferative Disorders

10.1136/jcp.2003.015479

Cite

Citations (1)

625 Platelet Mapping Thromboelastography for Individualized Antiplatelet Treatment after Implantation of the HeartWare Ventricular Assist Device

The Journal of Heart and Lung Transplantation (2011)

Bradley S. Gordon Tina Biss T. Butt Adam K McDiarmid F. Oezalp

Thromboelastography

10.1016/j.healun.2011.01.638

Cite

Citations (1)

Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding

Journal of Thrombosis and Haemostasis (2021)

Rachel J. Stapley Natalie S. Poulter Abdullah O. Khan Christopher W. Smith P Bignell

Platelet disorder

Candidate gene

Blood Platelet Disorders

Bernard–Soulier syndrome

Mean platelet volume

10.1111/jth.15584

Cite

Citations (5)

Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: a case report and review of the literature

Haemophilia (2006)

Tina Biss Mark Velangi John Hanley

Summary. We report the use of rituximab (MabThera ® ; Roche Grenzach‐Wyhlen, Germany) in a 6‐year‐old boy with severe haemophilia A and a high titre alloimmune factor VIII (FVIII) antibody, which had failed to respond to standard immune tolerance therapy. Rituximab was administered in 4 weekly doses with concurrent high‐dose i.v. immunoglobulin (Flebogamma ® ; Grifols, Barcelona, Spain) followed by daily high‐dose recombinant FVIII concentrate (Recombinate ® ; Baxter, CA, USA). Despite a fall in CD20 positive cell count to undetectable levels the inhibitor persisted. We discuss the possible reasons for failure of immune tolerance induction and review the literature concerning the use of rituximab for this indication.

Haemophilia B

10.1111/j.1365-2516.2006.01212.x

Cite

Citations (12)

Recombinant Activated Factor VII (rFVIIa) in the Management of Major Obstetric Haemorrhage: A Case Series and a Proposed Guideline for Use

Obstetrics and Gynecology International (2009)

Charlotte Bomken Sue Mathai Tina Biss Andrew Loughney John Hanley

Major obstetric haemorrhage remains a significant cause of maternal morbidity and mortality. Previous case reports suggest the potential benefit of recombinant activated factor VII (rFVIIa: ) as a haemostatic agent. We performed a retrospective review of the use of rVIIa in major obstetric haemorrhage in the Northern Region between July 2004 and February 2007. Fifteen women received rFVIIa. The median patient age was 34 years. Major haemorrhage occurred antepartum (5 patients), intrapartum (1), and postpartum (9). All women received an initial dose of 90 mcg/kg rFVIIa and one received 2 further doses. Bleeding stopped or decreased in 12 patients (80%). Additional measures included antifibrinolytic and uterotonic agents, Rusch balloon insertion, uterine curettage/packing, and vessel embolisation. Eight patients required hysterectomy. All women survived to discharge from hospital. No adverse events, including thrombosis, were recorded. This study provides further support for the safety and efficacy of rFVIIa as adjunct therapy in major obstetric haemorrhage.

Uterotonic

Guideline

10.1155/2009/364843

Cite

Citations (27)

Evaluation of the age‐dependent dosing recommendations for the administration of daily tinzaparin in children with thrombosis

Journal of Thrombosis and Haemostasis (2017)

Kathryn Musgrave Kat Webber Paul Murphy Peter Avery Tina Biss

10.1111/jth.13856

Cite

Citations (4)

Whole-genome sequencing of patients with rare diseases in a national health system

Nature (2020)

Ernest Turro William J. Astle Karyn Mégy Stefan Gräf Daniel Greene

10.1038/s41586-020-2434-2

Cite

Citations (443)

Apixaban overdose in children: case report and proposed management. A brief communication from the Pediatric and Neonatal Thrombosis and Hemostasis SSC of ISTH

Research and Practice in Thrombosis and Haemostasis (2024)

Meredith Wiggins Tina Biss Leslie Raffini C. Heleen van Ommen Anthony K.C. Chan

Essentials•Direct oral anticoagulant drugs such as apixaban are increasingly being prescribed.•Safety information on overdose of apixaban in children is important.•We discuss a case of apixaban overdose in a young child.•Recommendations for management of apixaban overdose in children are provided.AbstractBackgroundDirect oral anticoagulants are commonly prescribed for adults and increasingly also for children requiring anticoagulation therapy. While household medications should not be accessible to children, accidental, and intentional overdoses occur.Key Clinical QuestionHow should apixaban overdose in children be managed?.Clinical ApproachWe present a case of an accidental overdose with the factor Xa antagonist apixaban in a young child and propose an approach to the management of cases of apixaban overdose in children.ConclusionGiven the increasing use of direct oral anticoagulants, it is important to have an approach to the management of overdose of these medications.

Apixaban

10.1016/j.rpth.2023.102312

Cite

Citations (0)